{"id":"placebo-for-revefenacin","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL3833319","moleculeType":"Small molecule","molecularWeight":"597.76"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not interact with any biological molecules or systems. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"This is a placebo, meaning it has no active pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:19.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of chronic cough due to idiopathic pulmonary fibrosis"}]},"trialDetails":[{"nctId":"NCT07133880","phase":"PHASE4","title":"Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-12-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":72},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT02820311","phase":"PHASE1","title":"Thorough QT (TQT) Study of TD-4208 in Healthy Subjects","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2016-05","conditions":"Cardiac Repolarization in Healthy Subjects","enrollment":48},{"nctId":"NCT02459080","phase":"PHASE3","title":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":619},{"nctId":"NCT03095456","phase":"PHASE3","title":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2017-03-27","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)","enrollment":207},{"nctId":"NCT03573817","phase":"PHASE3","title":"A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2018-05-31","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT02109172","phase":"PHASE2","title":"A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":64},{"nctId":"NCT01704404","phase":"PHASE2","title":"7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2012-12","conditions":"COPD","enrollment":62},{"nctId":"NCT02512510","phase":"PHASE3","title":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":611}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Revefenacin","genericName":"Placebo for Revefenacin","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo, meaning it has no active pharmacological effect. Used for Treatment of chronic cough due to idiopathic pulmonary fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}